Anticholinergics, or antimuscarinic drugs, are drugs that competitively inhibit the action of acetylcholine at muscarinic receptors, leading to a blockade of the actions of the parasympathetic nervous system at sites where overactivity can lead to increased symptom burden. Successful blockade of the parasympathetic nervous system ultimately leads to decreased production of secretions in the salivary, bronchial, and gastrointestinal tracts. These effects are often used for several symptoms that originate due to parasympathetic nervous system overactivity, such as the “death rattle” and malignant bowel obstruction. Anticholinergic agents are divided into either tertiary amines or quaternary ammonium compounds, which differ in their ability to cross into the central nervous system. Quaternary compounds do not cross into the central nervous system and have a different adverse effect profile than the tertiary amines. The purpose of this review is to highlight anticholinergic agents, their pharmacology, and an evidence-based assessment of their role in palliative care.
BillingsJA. What is palliative care?J Palliat Med. 1998;1(1):73–81.
2.
ShahNKhuranaSChengKRaufmanJP. Muscarinic receptors and ligands in cancer. Am J Physiol Cell Physiol. 2009;296(2):C221–C232.
3.
RomplerHStaubertCThorDSchulzAHofreiterMSchonebergT. G protein-coupled time travel: evolutionary aspects of GPCR research. Mol Interv. 2007;7(1):17–25.
4.
BymasterFPMcKinzieDLFelderCCWessJ. Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem Res. 2003;28(3-4):437–442.
5.
AbramsPAnderssonKEBuccafuscoJJ. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006;148(5):565–578.
6.
IkedaKKobayashiSSuzukiM. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol. 2002;366(2):97–103.
7.
SutliffVERattanSGardnerJDJensenRT. Characterization of cholinergic receptors mediating pepsinogen secretion from chief cells. Am J Physiol. 1989;257(2 pt 1):G226–G234.
8.
SollAH. Specific inhibition by prostaglandins E2 and I2 of histamine-stimulated [14C] aminopyrine accumulation and cyclic adenosine monophosphate generation by isolated canine parietal cells. J Clin Invest. 1980;65(5):1222–1229.
9.
ZimmermanTWDobbinsJWBinderHJ. Mechanism of cholinergic regulation of electrolyte transport in rat colon in vitro. Am J Physiol. 1982;242(2):G116–G123.
10.
BrownJHLaikenN. Muscarinic Receptor Agonists and Antagonists. In: (2011). Chapter 9. In BruntonLLChabnerBAKnollmannBC eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed.2011. http://www.accessmedicine.com/content.aspx?aID@=16660596. Accessed September 3, 2012.
11.
Ali-MelkkiläTKantoJIisaloE. Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Acta Anaesthesiol Scand. 1993;37(7):633–642.
12.
MerelloMFarberNMRonES. methods and compositions for decreasing saliva production. Google patents. January 19, 2006.
13.
DavisMPNounehC. Modern management of cancer-related intestinal obstruction. Curr Oncol Rep. 2000;2(4):343–350.
14.
HaddadEBPatelHKeelingJEYacoubMHBarnesPJBelvisiMG.Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways. Br J Pharmacol. 1999;127(2):413–420.
15.
NachumZShahalBShupakA. Scopolamine bioavailability in combined oral and transdermal delivery. J Pharmacol Exp Ther. 2001;296(1):121–123.
16.
Micromedix atropine. Micromedex®Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Reuters (Healthcare) Inc; 2010. Updated periodically.
17.
Micromedix scopolamine. Micromedex® Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Reuters (Healthcare) Inc; 2010. Updated periodically.
18.
Micromedix hyoscine butylbromide. Micromedex® Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Reuters (Healthcare) Inc; 2010. Updated periodically.
19.
PutchaLCintrónNMTsuiJVanderploegJMKramerWG. Pharmacokinetics and oral bioavailability of scopolamine in normal subjects. Pharm Res. 1989;6(6):481–485.
20.
RennerUDOertelRKirchW. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. Ther Drug Monit. 2005;27(5):655–665.
21.
EbertUSiepmannMOertelRWesnesKAKirchW. Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration. J Clin Pharmacol. 1998;38(8):720–726.
22.
EbertUOertelRKirchW. Influence of grapefruit juice on scopolamine pharmacokinetics and pharmacodynamics in healthy male and female subjects. Int J Clin Pharmacol Ther. 2000;38(11):523–531.
23.
EbertUGrossmannMOertelRGramatteTKirchW. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers. J Clin Pharmacol. 2001;41(1):51–60.
24.
ParrottAC. Transdermal scopolamine: a review of its effects upon motion sickness, psychological performance, and physiological functioning. Aviat Space Environ Med. 1989;60(1):1–9.
25.
Ali-MelkkilS TKailaTKantoJ.Glycopyrrolate: pharmacokinetics and some pharmacodynamic findings. Acta Anaesthesiol Scand. 1989;33(6):513–517.
26.
DickmanASchneiderJVargaJ. The Syringe Driver: Continuous Subcutaneous Infusions in Palliative Care. USA: Oxford University Press; 2005.
27.
Ali-MelkkilaTMKailaTKantoJIisaloE. Pharmacokinetics of im glycopyrronium. Br J Anaesth. 1990;64(6):667–669.
28.
KaltialaEPenttilSAVapaataloHLarmiT. The fate of intravenous (3H) glycopyrrolate in man. J Pharm Pharmacol. 1974;26(5):352–354.
29.
BeermannBHellströmKRosenA. The gastrointestinal absorption of atropine in man. Clin Sci. 1971;40(1):95–106.
30.
KentalaEKailaTIisaloEKantoJ. Intramuscular atropine in healthy volunteers: a pharmacokinetic and pharmacodynamic study. Int J Clin Pharmacol Ther Toxicol. 1990;28(9):399–404.
31.
EbertUSiepmannMOertelRWesnesKAKirchW. Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration. J Clin Pharmacol. 1998;38(8):720–726.
32.
BerghemLBerghemUSchildtBSorboB. Plasma atropine concentrations determined by radioimmunoassay after single-dose iv and im administration. Br J Anaesth. 1980;52(6):597–601.
33.
AdamsRGVermaPJacksonAJMillerRL. Plasma pharmacokinetics of intravenously administered atropine in normal human subjects. J Clin Pharmacol. 1982;22(10):477–481.
34.
KantoJ. Oropharyngeal absorption of atropine. Int J Clin Pharmacol Ther Toxicol. 1986;24(11):627–629.
35.
BrayBMJonesHMGrundyEM. Tracheal versus intravenous atropine. Anaesthesia. 1987;42(11):1188–1190.
36.
HarrisonLISmallridgeRCLasseterKC. Comparative absorption of inhaled and intramuscularly administered atropine. Am Rev Respir Dis. 1986;134(2):254–257.
37.
TytgatGN. Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. Drugs. 2007;67(9):1343–1357.
38.
HerxheimerADe GrootAC. Some effects of injected hyoscine butylbromide: a versatile class experiment in human pharmacology. Br J Clin Pharmacol. 1977;4(3):337–342.
39.
KentalaEKailaTAli-MelkkilS TKantoJ.beta-Glucuronide and sulfate conjugation of scopolamine and glycopyrrolate. Int J Clin Pharmacol Ther Toxicol. 1990;28(11):487–489.
40.
KalserSCMcLainPL. Atropine metabolism in man. Clin Pharmacol Ther. 1970;11(2):214–227.
41.
KirvelaMAli-MelkkilaTKailaTIisaloELindgrenL. Pharmacokinetics of glycopyrronium in uraemic patients. Br J Anaesth. 1993;71(3):437–439.
42.
HinderlingPHGundert-RemyUSchmidlinyOHeinzelG. Integrated pharmacokinetics and pharmacodynamics of atropine in healthy humans II: pharmacodynamics. J Pharm Sci. 1985;74(7):711–717.
43.
OlsenAKSjøgrenP. Oral glycopyrrolate alleviates drooling in a patient with tongue cancer. J Pain Symptom Manage. 1999;18(4):300–302.
44.
SeymourRMRoutledgePA. Important drug-drug interactions in the elderly. Drugs Aging. 1998;12(6):485–494.
45.
LikarRRupacherEKagerHMolnarMPipamWSittlR.Die Wirkung von Glycopyrroniumbromid im Vergleich mit Scopolamin-Hydrobromicum beim terminalen Rasseln: Eine randomisierte, doppelblinde Pilotstudie. Wien Klin Wochenschr. 2008;120(21-22):679–683.
46.
BackINJenkinsKBlowerABeckhellingJ. A study comparing hyoscine hydrobromide and glycopyrrolate in the treatment of death rattle. Palliat Med. 2001;15(4):329–336.
47.
HughesAWilcockACorcoranRLucasVKingA. Audit of three antimuscarinic drugs for managing retained secretions. Palliat Med. 2000;14(3):221–222.
48.
HugelHEllershawJGamblesM. Respiratory tract secretions in the dying patient: a comparison between glycopyrronium and hyoscine hydrobromide. J Palliat Med. 2006;9(2):279–284.
49.
WildiersHDhaenekintCDemeulenaereP. Atropine, hyoscine butylbromide, or scopolamine are equally effective for the treatment of death rattle in terminal care. J Pain Symptom Manage. 2009;38(1):124–133.
50.
ClarkKCurrowDCAgarMFazekasBSAbernethyAP. A pilot phase II randomized, cross-over, double-blinded, controlled efficacy study of octreotide versus hyoscine hydrobromide for control of noisy breathing at the end-of-life. J Pain Palliat Care Pharmacother. 2008;22(2):131–138.
51.
De SimoneGGEisenchlasJHJuninMPereyraFBrizuelaR. Atropine drops for drooling: a randomized controlled trial. Palliat Med. 2006;20(7):665–671.
52.
MystakidouKTsilikaEKalaidopoulouOChondrosKGeorgakiSPapadimitriouL. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double-blind, controlled clinical trial. Anticancer Res. 2002;22(2B):1187–1192.
53.
MercadanteSRipamontiCCasuccioAZeccaEGroffL. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer. 2000;8(3):188–191.
54.
BachrachSJWalterRSTrzcinskiK. Use of glycopyrrolate and other anticholinergic medications for sialorrhea in children with cerebral palsy. Clin Pediatr (Phila). 1998;37(8):485–490.
55.
RougierPBugatRDouillardJY. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol. 1997;15(1):251–260.
56.
BauweseinCTwycrossRG. Comparative cost of hyoscine injections. Palliat Med. 1995;9(3):256.
